Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: Analysis conducted on the United Kingdom General Practitioner Research Database

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 3009-3016

  Lafuma, A ^a   Berdeaux, Gilles ^b  

^a CEMKA EVAL   (France)

^b Alcon France   (France)

Author keywords

Costs; Economics; Effectiveness; Glaucoma; Timolol dorzolamide; Travoprost; UK GPRD

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; TRAVOPROST;

COMORBIDITY; CONFERENCE PAPER; DATA BASE; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; SEX DIFFERENCE; TREATMENT FAILURE;

AGED; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DRUG COMBINATIONS; DRUG COSTS; FEMALE; GLAUCOMA; GREAT BRITAIN; HUMANS; MALE; PHYSICIANS, FAMILY; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 37749022093     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242836     Document Type: Conference Paper

References (30)

1. Diestelhort JS, Hughes GM. Open-angle glaucoma. Am Fam Phys 2003;67:1937-44
2. Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998;105:2099-104
3. Broman AT, Quigley HA. The number of people with glaucoma worldwide in 2010 and Br J Ophthalmol 2006;90:253-4
4. Coyle D, Drummond M. The economic burden of glaucoma in the UK. The need for a far-sighted policy. Pharmacoeconomics 1995;7:484-9
5. Kobelt G, Jonsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998;236:811-21
6. Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004;13:283-90
7. Jönsson B, Krieglstein G. Primary open-angle glaucoma-differences in international treatment patterns and costs. Oxford: Isis Medical Media, 1998
8. Kooner KS, Zimmerman TJ. The cost of antiglaucoma medications. Ann Ophthalmol 1987;19:327-8
9. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch of Ophthalmol 2002;120:701-13
10. The European Glaucoma Prevention Study (EGPS) group. Results of the European Glaucoma Prevention Study. Ophthalmology 2005;112:366-75
11. The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS). Report #13: Comparison of treatment outcomes within race: 10-year results. Ophthalmology 2004;111:651-64
12. Heijl A, Leske MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79
13. Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56
14. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40
15. Suzuki ER Jr, Franklin LM, da Silva LJ, et al. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin 2006;22:1799-805
16. Chiselita D, Antohi I, Medvichi R, et al. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia 2005;49:39-45
17. Parmaksiz S, Yuksel N, Karabas VL, et al. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006;16:73-80
18. Hjelmgren J, Berggren F, Andersson D. Health Economics guidelines - Similarities, differences and some implications. Values in Health 2001;4:225-50
19. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 2006;22:971-6
20. Deschaseaux-Voinet C, Lafuma A, Berdeaux G. Cost and effectiveness of brinzolamide versus dorzolamide in current practice: an analysis based on the UK-GPRD data base. J Med Econom 2003:6:69-78
21. Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006;141(1 Suppl):S28-33
22. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005;140:598-606
23. http://www.gprd.com/home/
24. Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies. J Biopharm Stat 2007;17:1-13; discussion 15-7, 19-21, 23-7 passim
25. British National Formulary. London BMJ Publishing Group, 2007
26. Statistics of OECD http://www.oecd.org/
27. Curtis L, Netten A. Units costs of health and social care 2005 PSSRU University of Kent. (http://www.pssru.ac.uk/)
28. European Medicines Agency. European Public Assessment Report (EPAR). http://www.emea.europa.eu/htms/human/epar/a.htm
29. Robin AL, Covert D Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863-8
30. Rouland JF, Le Pen C, Gouveia Pinto, et al. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open glaucoma in 4 European countries. PharmacoEconom 2003;21:201-13